Two new IgA1-kappa plasma cell leukaemia cell lines (JJN-1 & JJN-2) which proliferate in response to B cell stimulatory factor 2.
Two new cell lines with the phenotype of terminally differentiated B cells have been derived from the presentation bone marrow of a patient with plasma cell leukaemia. They express the same immunoglobulin (A1-kappa) as the original bone marrow cells. JJN-1 is an hypodiploid, slow-growing line with a plasmacytic morphology, which grows in medium with 15-20% fetal calf serum. When JJN-1 was stimulated with a supernatant ('ESG') containing B cell stimulatory factor 2 (BSF-2/IL-6), a hypotetraploid sub-line, JJN-2, was selectively stimulated. JJN-2 is dependent on ESG for survival. The stimulatory effect of ESG can be completely abrogated by an anti-BSF-2 monoclonal antibody. However, purified BSF-2 alone only produces sub-maximal stimulation of the lines. Both lines show complex karyotypic abnormalities, including 14q- and del(6q). JJN-1 and JJN-2 may be useful for the study of late B cell differentiation and for use as immunogens for the generation of anti-plasma cell monoclonal antibodies.
Jackson
N
N
Department of Haematology, Medical School, Birmingham, UK.
Lowe
J
J
Ball
J
J
Bromidge
E
E
Ling
N R
NR
Larkins
S
S
Griffith
M J
MJ
Franklin
I M
IM
D000954:Antigens, Surface / Q000032:analysis; D001402:B-Lymphocytes / Q000276:immunology; D002460:Cell Line; D004273:DNA, Neoplasm / Q000032:analysis; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology*; D007145:Immunoglobulin kappa-Chains / Q000276:immunology; D015850:Interleukin-6; D007378:Interleukins / Q000494:pharmacology*; D007621:Karyotyping; D007952:Leukemia, Plasma Cell / Q000276:immunology*; D008875:Middle Aged; D008938:Mitosis / Q000187:drug effects; D014407:Tumor Cells, Cultured
D000954:Antigens, Surface; D004273:DNA, Neoplasm; D007070:Immunoglobulin A; D007145:Immunoglobulin kappa-Chains; D015850:Interleukin-6; D007378:Interleukins